Literature DB >> 1956463

Immune regulation of mouse 5T2 multiple myeloma. I. Immune response to 5T2 MM idiotype.

J W Croese1, C S Vissinga, W J Boersma, J Radl.   

Abstract

The transplantable murine multiple myelomas (MM) of the 5T series originated spontaneously in the aging C57BL/KaLwRij mice. These murine malignancies offer an excellent model for experimental studies on different aspects of the human disease. With the aim to look for new treatment modalities, the influence of idiotype-specific immune response on the 'take' and the development of the 5T2 MM was studied. In the first experiment, long-lasting subcutaneous immunizations of syngeneic mice with the 5T2 MM immunoglobulin (Ig) showed a dose dependent anti 5T2 MM Ig idiotype-specific response. The majority of the optimally immunized mice showed no 'take' or they had a prolonged survival after intravenous inoculation with the 5T2 MM cells. All control mice, nonimmunized or immunized with an irrelevant 5T14 MM Ig, developed 5T2 MM with a typical lethal course. In the second experiment, delayed type hypersensitivity (DTH) reaction to the 5T2 MM idiotype was studied. Subcutaneous immunizations of syngeneic mice with 5T2 MM Ig or with 5T2 MM bone marrow cells resulted in a specific DTH reaction 48 hours after challenge with 5T2 MM bone marrow cells. No DTH reaction was obtained when intravenous immunization was used. These results indicate that 5T2 MM is sensitive to idiotype-specific immune regulation; they constitute a basis for further studies on treatment of already established MM in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1956463

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  5 in total

1.  GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model.

Authors:  H R Galea; M Cogné
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

2.  Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule.

Authors:  S Morecki; S Levi; Y Puyesky; S Slavin
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

3.  Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells.

Authors:  L S Manning; N S Radin
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

Review 4.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

5.  A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse.

Authors:  L S Manning; J D Berger; H L O'Donoghue; G N Sheridan; P G Claringbold; J H Turner
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.